Layal Rached, Ariane Laparra, Madona Sakkal, François-Xavier Danlos, Fabrice Barlesi, Franck Carbonnel, Eleonora De Martin, Michel Ducreux, Caroline Even, Jerome Le Pavec, Jean-Marie Michot, Joana M Ribeiro, Florian Scotte, Santiago Ponce Aix, Olivier Lambotte, Capucine Baldini, Stéphane Champiat
Chemotherapy associated with Immune Checkpoint Inhibitors is currently the standard of care in several tumor indications. This combination approach improves progression free survival (PFS), overall survival (OS) and complete pathological response (pCR) in several cancer types both in the early and metastatic approaches. However, the distinct spectrum of toxicities between cytotoxic side effects and immune related adverse events (irAEs) with similar clinical presentations and different management strategies remains a challenge in daily practice for healthcare professionals...
May 4, 2024: Cancer Treatment Reviews